Image de couverture de livre

Commentary on Östh et al.: Sensor‐based approaches to inform alcohol interventions – beyond BAC

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Brian Suffoletto
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Addiction
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Commentary on Aubin et al.: Could combination medication approaches target mental health comorbidity in the context of alcohol use disorder?
par: Shalini Arunogiri, et autres
Publié: (2024)

Commentary on Andreacchi et al.: Policy responses to shifting epidemiological trends in alcohol use in Canada
par: Carolin Kilian, et autres
Publié: (2024)

Commentary on ter Laak et al .: The importance of drug market information and differentiating drug use patterns
par: Rory Verhagen, et autres
Publié: (2024)

Commentary on Dobbie et al .: Preventing adolescent gambling‐related harm—Is a universal approach sufficient?
par: Jérémie Richard
Publié: (2026)

Commentary on Metcalfe et al.: ‘What works in AOD is when it feels like I am driving’ (Craig W, alcohol and drug peer worker)
par: Jeremy S. Hayllar
Publié: (2024)

Commentary on Ezard et al.: Agonist‐based medications for stimulant use disorder—Distinguishing their true colours
par: Vitor S. Tardelli, et autres
Publié: (2025)

Commentary on Serre et al . : Demonstrating the next era of addiction science
par: Bryant M. Stone, et autres
Publié: (2024)

Commentary on Getty et al .: Complementarity of harm reduction and contingency management
par: John M. Roll
Publié: (2026)

Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions
par: Paolo Mannelli
Publié: (2024)

Commentary on Jackson et al.: The role of regional tobacco control in centralised nations
par: Nathan Davies, et autres
Publié: (2025)

Commentary on Baltes‐Flueckiger et al.: Rethinking expectations and evidence in cannabis policy
par: Sharon R. Sznitman, et autres
Publié: (2025)

Commentary on Morris et al .: Shifting consumption from unhealthy to healthy commodities
par: Daniel Araya‐Ríos
Publié: (2026)

Commentary on Manthey et al .: No more missed opportunities—We need to address the absence of robust and comprehensive evaluations about the real‐world impact of statutory restrictions on alcohol marketing
par: Nathan Critchlow
Publié: (2024)

Commentary on Rehm et al.: Utilizing return on investment analysis to advocate for tax increases
par: Meenakshi S. Subbaraman
Publié: (2025)

Commentary on Nieto et al .: The heterogeneity of drug craving and considerations as a treatment endpoint
par: Justin C. Strickland, et autres
Publié: (2026)

A detox dilemma beyond benzodiazepines; clonidine's quandary in alcohol withdrawal management
par: Matthew Johnson, et autres
Publié: (2024)

Misleading conclusion from limited research approach: Comment on Manthey et al. ‘Restricting alcohol marketing to reduce alcohol consumption: A systematic review of the empirical evidence for one of the “best buys”’
par: Sally Casswell
Publié: (2024)

Commentary on Giné et al .: The hidden face of overdose: Gender inequities along the continuum of care
par: Patrizia Carrieri, et autres
Publié: (2025)

Commentary on Coelho et al .: Ecological momentary assessments may be key to the future of cannabis studies
par: Lucy Chester, et autres
Publié: (2025)

Commentary on Stam et al .: The substantial and dynamic contribution of opioid potency to total overdose risk
par: Phillip O. Coffin
Publié: (2024)

Commentary on Qeadan et al .: Leveraging opportunities to expand the substance use disorder treatment arsenal
par: Ty S. Schepis
Publié: (2024)

Commentary on Gregory et al .: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation
par: Sandra A. Springer
Publié: (2024)

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling
par: Rachel Lees Thorne, et autres
Publié: (2025)

Commentary on Ezard et al.: Prescribed psychostimulant medications for methamphetamine use disorder – an urgent path forward
par: Adam Bisaga
Publié: (2025)

Commentary on Day et al.: Systemic solutions for recovery support services in Ireland's National Drug Strategy
par: Jo‐Hanna H. Ivers
Publié: (2025)

Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy
par: Nadine Ezard, et autres
Publié: (2025)

Commentary on Lim et al .: Real‐world e‐cigarette use under prescription‐only regulation
par: Dimitra Kale, et autres
Publié: (2026)

Commentary on Carrasquilla et al.: Smoking and obesity; uncovering causal mechanisms through triangulation of different methods
par: Margot P. van de Weijer, et autres
Publié: (2024)

Commentary on Craft et al.: Drug contaminants and substitutions in illicit vapes represent a major health risk
par: Caroline S. Copeland
Publié: (2025)

Commentary on Amin‐Esmaeili et al .: Non‐abstinence outcomes in stimulant clinical trials—Why deny improvement?
par: Vítor S. Tardelli
Publié: (2024)

Commentary on Zhu et al .: Nitazenes—Tracking a moving target from linked United States databases
par: Christophe P. Stove, et autres
Publié: (2026)

Commentary on Dowd et al .: Beyond single data sources—Consistency checking and evidence synthesis for prevalence estimation
par: Hayley E. Jones, et autres
Publié: (2026)

A scoping review of sensory‐based interventions to address alcohol consumption
par: Natcha Chaikhamla, et autres
Publié: (2025)

Commentary on Dennett et al .: When heat and the opioid epidemic collide ‐ implications for climate‐resilient public health strategies
par: Tarik Benmarhnia
Publié: (2025)

Commentary on Bade et al.: Threat of nitazenes and other potent synthetic opioids—Is Europe prepared? Time to respond and to learn
par: Isabelle Giraudon, et autres
Publié: (2025)

Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals
par: Jake R. Morgan, et autres
Publié: (2024)

Commentary on Mereish et al .: Supporting sexually diverse youth requires a full spectrum understanding of substance use
par: Kira London‐Nadeau, et autres
Publié: (2026)

Commentary on Copeland et al.: Does xylazine in the United Kingdom foreshadow a European synthetic polysubstance drug crisis?
par: Joseph R. Friedman
Publié: (2024)

Commentary on Conde et al.: Evidence and gap map offer an important opportunity for dialogue and refinement of the gateway hypothesis controversy
par: Arielle Selya, et autres
Publié: (2024)

Commentary on He et al .: From static association to dynamic causation ‐ a methodological leap in understanding and addressing addiction
par: Zihan Lv, et autres
Publié: (2026)